Comprehensive split TEV based protein-protein interaction screening reveals TAOK2 as a key modulator of Hippo signalling to limit growth

Cell Signal. 2024 Jan:113:110917. doi: 10.1016/j.cellsig.2023.110917. Epub 2023 Oct 7.

Abstract

The conserved Hippo signalling pathway plays a crucial role in tumour formation by limiting tissue growth and proliferation. At the core of this pathway are tumour suppressor kinases STK3/4 and LATS1/2, which limit the activity of the oncogene YAP1, the primary downstream effector. Here, we employed a split TEV-based protein-protein interaction screen to assess the physical interactions among 28 key Hippo pathway components and potential upstream modulators. This screen led us to the discovery of TAOK2 as pivotal modulator of Hippo signalling, as it binds to the pathway's core kinases, STK3/4 and LATS1/2, and leads to their phosphorylation. Specifically, our findings revealed that TAOK2 binds to and phosphorylates LATS1, resulting in the reduction of YAP1 phosphorylation and subsequent transcription of oncogenes. Consequently, this decrease led to a decrease in cell proliferation and migration. Interestingly, a correlation was observed between reduced TAOK2 expression and decreased patient survival time in certain types of human cancers, including lung and kidney cancer as well as glioma. Moreover, in cellular models corresponding to these cancer types the downregulation of TAOK2 by CRISPR inhibition led to reduced phosphorylation of LATS1 and increased proliferation rates, supporting TAOK2's role as tumour suppressor gene. By contrast, overexpression of TAOK2 in these cellular models lead to increased phospho-LATS1 but reduced cell proliferation. As TAOK2 is a druggable kinase, targeting TAOK2 could serve as an attractive pharmacological approach to modulate cell growth and potentially offer strategies for combating cancer.

Keywords: Cell proliferation; Cell-based assay; Hippo signalling; LATS1; Protein-protein interaction; Split TEV assay; TAO kinases; TAOK2; Tumour suppressor; YAP1; cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Renal Cell*
  • Cell Proliferation
  • Hippo Signaling Pathway
  • Humans
  • Kidney Neoplasms*
  • Protein Serine-Threonine Kinases / metabolism
  • Serine-Threonine Kinase 3
  • Signal Transduction / genetics

Substances

  • Protein Serine-Threonine Kinases
  • Serine-Threonine Kinase 3
  • STK3 protein, human
  • TAOK2 protein, human